Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Jun;27(6):1830-6.
doi: 10.1681/ASN.2015040426. Epub 2015 Oct 14.

Long-Term Effects of Frequent In-Center Hemodialysis

Affiliations
Randomized Controlled Trial

Long-Term Effects of Frequent In-Center Hemodialysis

Glenn M Chertow et al. J Am Soc Nephrol. 2016 Jun.

Abstract

The Frequent Hemodialysis Network Daily Trial randomized 245 patients to receive six (frequent) or three (conventional) in-center hemodialysis sessions per week for 12 months. As reported previously, frequent in-center hemodialysis yielded favorable effects on the coprimary composite outcomes of death or change in left ventricular mass and death or change in self-reported physical health. Here, we determined the long-term effects of the 12-month frequent in-center hemodialysis intervention. We determined the vital status of patients over a median of 3.6 years (10%-90% range, 1.5-5.3 years) after randomization. Using an intention to treat analysis, we compared the mortality hazard in randomized groups. In a subset of patients from both groups, we reassessed left ventricular mass and self-reported physical health a year or more after completion of the intervention; 20 of 125 patients (16%) randomized to frequent hemodialysis died during the combined trial and post-trial observation periods in contrast to 34 of 120 patients (28%) randomized to conventional hemodialysis. The relative mortality hazard for frequent versus conventional hemodialysis was 0.54 (95% confidence interval, 0.31 to 0.93); with censoring of time after kidney transplantation, the relative hazard was 0.56 (95% confidence interval, 0.32 to 0.99). Bayesian analysis suggested a relatively high probability of clinically significant benefit and a very low probability of harm with frequent hemodialysis. In conclusion, a 12-month frequent in-center hemodialysis intervention significantly reduced long-term mortality, suggesting that frequent hemodialysis may benefit selected patients with ESRD.

Keywords: clinical trial; end-stage renal disease; hemodialysis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT diagram. Disposition of Study Subjects. Consolidated Standards of Reporting Trials diagram. HD, hemodialysis.
Figure 2.
Figure 2.
Kaplan-Meier curves depicting survival of patients randomized to the frequent and conventional hemodialysis groups. (A) Displays the survival curves including follow-up after transplantation; (B) displays the survival curves with follow-up censored at transplantation. The relative hazards were computed using Cox proportional hazards regression. HR, hazard ratio.
Figure 3.
Figure 3.
Posterior distributions of the relative hazard comparing mortality during extended follow-up among patients randomized to frequent and conventional hemodialysis under prior distributions representing neutral (A) and optimistic (B) perspectives on the probability of a treatment benefit. The posterior distributions characterize the implications of the observed relative hazard of 0.54 (downward pointing arrow) for individuals with the perspectives indicated by the conservative and enthusiastic priors before observing the results. The posterior probabilities of harm (black region), a small benefit with relative hazard between 0.8 and 1 (gray region), and a substantial benefit with relative hazard ≤0.8 are 0.07, 0.32, and 0.61, respectively, under the neutral prior and 0.02, 0.11, and 0.87, respectively, under the optimistic prior.

References

    1. US Renal Data System: USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013. Available at: http://www.usrds.org. Accessed July 1, 2014
    1. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, Go AS, Chertow GM: Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 68: 2801–2808, 2005 - PubMed
    1. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R Hemodialysis (HEMO) Study Group : Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010–2019, 2002 - PubMed
    1. Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, Dwyer JT, Kimmel PL, Kusek JW, Martin A, Rehm-McGillicuddy J, Teehan BP, Meyer KB HEMO Study Group : Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int 66: 355–366, 2004 - PubMed
    1. Buoncristiani U, Quintaliani G, Cozzari M, Giombini L, Ragaiolo M: Daily dialysis: Long-term clinical metabolic results. Kidney Int Suppl 24: S137–S140, 1988 - PubMed

Publication types